Sernova Secures $1M Convertible Debt Financing
Sernova Biotherapeutics secured a CAD$1,000,000 convertible debenture financing from existing shareholder and board member, Dr. Steven Sangha. The proceeds...
Jon Napitupulu
Journey Medical’s Emrosi™ Rosacea Trial Results Published in JAMA Dermatology
Journey Medical Corporation announced positive Phase 3 trial results for its rosacea treatment, Emrosi (DFD-29), published in JAMA Dermatology....
Vaxart’s Oral Norovirus Vaccine Shows Promise in Elderly Adults
Vaxart, Inc. announced complete data from a Phase 1b trial of its oral norovirus vaccine candidate in older adults,...
Tenax Advances Oral Levosimendan in Phase 3 PH-HFpEF Studies
Tenax Therapeutics announced the FDA’s acceptance of an amendment to expand its Phase 3 LEVEL study for TNX-103 (oral...
Silexion Therapeutics Reports Positive Initial Data from Sil204 in Pancreatic Cancer Models
Silexion Therapeutics (NASDAQ: SLXN) has released positive preclinical data for SIL204, its RNAi therapy targeting KRAS-driven cancers. The study...
Vafidemstat Shows Promise in Phelan-McDermid Syndrome Patients
A study published in Frontiers in Psychiatry characterized the psychometric profiles of 30 individuals with Phelan-McDermid Syndrome (PMS), identifying...
Zyversa Demonstrates NLRP3 Inhibition Improves Heart Function, Glucose Homeostasis, and Insulin Sensitivity in Obese Animal Model
ZyVersa Therapeutics highlighted newly published data demonstrating the cardioprotective and metabolic benefits of inhibiting NLRP3 inflammasome pathways in an...
Invivyd Announces Neutralizing Activity of Pemigarda Against Dominant SARS-CoV-2 Variant
Invivyd announced positive in vitro neutralization data for its COVID-19 antibody treatment, PEMGARDA (pemivibart), against the dominant LP.8.1 variant....
Garuda Therapeutics Secures $50M to Advance Blood Stem Cell Therapies
Garuda Therapeutics secured $50 million in Series A-1 funding to develop off-the-shelf hematopoietic stem cell (HSC) therapies for various...
Enlivex Therapeutics Announces Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Enlivex Therapeutics announced positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis. The trial showed...